Clinical Trials Logo
  1. Home
  2. Follicular Lymphoma
  3. NCT05529524
  4. Details
NCT05529524 Clinical Trial

Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)

Follicular Lymphoma Clinical Trial

Official title:
Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05529524
Other study ID # CALC
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 7, 2022
Est. completion date September 1, 2024

Study information
Verified date March 2024
Source The Lymphoma Academic Research Organisation
Contact Myriem Chikhaoui, Msc
Phone +33683444031
Email myriem.chikhaoui@lysarc.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Mosunetuzumab is a T-cell bispecific antibody targeting CD20 and CD3 aiming to redirect T cells to engage and eliminate malignant B cells. Bispecific antibodies (BsAb) are a promising treatment option which can induce long-term responses in refractory and relapsed B cell lymphoma patients. However, the factors determining the quality and duration of responses are poorly understood.

Description:

the objective is to produce a collection of great scientific interest for lymphoma research from CELESTIMO's clinical trial patients' samples to increase knowledge of treatment with mosunetuzumab's for patients with follicular lymphoma (FL). study population involves patients participating to CELESTIMO study in France. 10 sites are expected in this biobanking protocol study Biological samples will collected as part of routine care (tissue and blood already sampled in routine and/or CELESTIMO study) at screening, at C4, at C12 or at progressive disease/relapse.

Recruitment information / eligibility
Status Recruiting
Enrollment 40
Est. completion date September 1, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility patients who participate to CELESTIMO study (NCT04712097)

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France Centre Hospitalier de La Cote Basque; Hematologie Bayonne
France Hopital Claude Huriez; Hematologie Lille
France Institut Paoli Calmettes Marseille
France CHU Saint Eloi; Service d'Hématologie Clinique Montpellier
France CHU NANTES - Hôtel Dieu; Service d'Hematologie Clinique Nantes cedex 1
France CHU de Nîmes - Hôpital Carémeau Nîmes
France Hopital Saint Antoine; Hematologie Clinique Paris
France Hopital De La Miletrie; Hematologie Et Oncologie Medicale Poitiers
France CHU Pontchaillou Rennes

Sponsors (2)
Lead Sponsor Collaborator
The Lymphoma Academic Research Organisation Roche Pharma AG

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Capacity of sampling number of samples collected 2 years
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Active, not recruiting NCT03078855 - A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Phase 3
Active, not recruiting NCT03245021 - Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A Phase 1
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT02213263 - A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) Phase 3
Completed NCT01691898 - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Terminated NCT03585725 - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Early Phase 1
Terminated NCT00772668 - Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL N/A
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Terminated NCT02204982 - Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma Phase 3
Completed NCT02536664 - Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants
Terminated NCT00850499 - Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab Phase 2
Terminated NCT00475332 - Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar Phase 2
Terminated NCT00136591 - A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma Phase 2
Not yet recruiting NCT06068881 - A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation Phase 2
Completed NCT04034056 - Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)